Could Carbon Monoxide Protect Against Anesthesia-Induced Neuroapoptosis?
'Physiologic' CO Levels Might Be Protective in Immature Brains, Suggest Study and Editorial in Anesthesia & Analgesia
Article ID: 618154
Released: 21-May-2014 10:00 AM EDT
Source Newsroom: International Anesthesia Research Society (IARS)
Newswise — Montréal, Canada (May 21, 2014) – Basic science research suggests a promising, if surprising, method to protect against anesthesia-induced developmental neurotoxicity: subclinical carbon monoxide (CO) inhalation, according to a report and accompanying editorial published in the June 2014 issue of Anesthesia & Analgesia, the official journal of the International Anesthesia Research Society (IARS).
Low concentrations of CO limit apoptosis after isoflurane exposure in immature mice, through a mechanism of cytochrome c peroxidase inhibition, according to a recent paper by Drs Ying Cheng and Richard J. Levy of Children's National Medical Center, Washington, DC.
In a new editorial, Dr Vesna Jevtovic-Todorovic of University of Virginia Health System, Charlottesville, discusses the prospect of using CO—a potentially lethal gas—to protect the brains of infants and children during anesthesia and surgery. She writes, "The major advance provided by improved understanding of anesthetic-induced neurodegeneration is the potential to design clinically attainable methods to protect against anesthesia-induced developmental neurotoxicity."
Carbon Monoxide Reduces Brain Cell Apoptosis
Copies of the original research paper and editorial are available at this week's IARS 2014 Annual Meeting and International Science Symposium in Montreal. The study by Cheng and Levy was published ahead of print on the journal website www.anesthesia-analgesia.org.
In their study, Cheng and Levy found that isoflurane increased brain cell apoptosis in mouse pups, in association with increases in cytochrome c peroxidase activity and cytochrome c release. However, the increases in apoptosis as well as the cytochrome c changes were significantly reduced with concomitant exposure to "subclinical" levels of inhaled CO.
The findings may have implications for ongoing efforts to protect developing brains from possible damaging effects of anesthetic agents. In her editorial, Dr Jevtovic-Todorovic summarizes the evidence on anesthesia-induced neurotoxicity, with morphologic changes associated with later cognitive impairments. She writes, "There is urgency to improve our understanding of the mechanisms responsible for the neurotoxicity so that the most effective strategies can be introduced into clinical practice."
Funding research to improve the safety of pediatric anesthesia is the objective of the SmartTots initiative, sponsored by the IARS in partnership with the FDA. Dr Jevtovic-Todorovic is a member of the SmartTots Scientific Advisory Board.
Insights into Mechanism of Anesthesia-Induced Neurotoxicity
Based on the report by Cheng and Levy, isoflurane-induced up-regulation of cytochrome c peroxidase activity may be the first step in a cascade of events leading to neuroapoptotic degeneration. In their experiments, a 5 ppm concentration of inhaled CO led to significant reduction in markers of apoptosis—without causing a carboxyhemoglobin levels known to be harmful in humans.
A 100 ppm concentration of CO led to an additional decrease in isoflurane-induced apoptosis, but with higher carboxyhemoglobin levels. "Nevertheless, the authors claim that both low (5 ppm) and higher (100 ppm) concentrations of CO should be considered subclinical and not harmful," Dr Jevtovic-Todorovic writes.
Dr Jevtovic-Todorovic acknowledges that the concept of using carbon monoxide as a protective agent "may seem extreme," based on the devastating effects of CO asphyxia. She also notes some important limitations of the scientific evidence so far—particularly the lack of data on whether CO protects against isoflurane-induced cognitive impairment. She concludes, "This study addresses an important issue in developmental neurobiology and moves us a step closer to understanding the pathways responsible for anesthesia-induced neuroapoptosis."
About Anesthesia & Analgesia
Anesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARS
The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly journal Anesthesia & Analgesia in print and online.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
# # #